{
  "findings": [
    {
      "id": "Q01",
      "metric": "Fraction of tumor proteins represented in immunopeptidome",
      "value": "62.3%",
      "comparator_or_baseline": "37.3% (comparator)",
      "interpretation": "Intratumoral mRNA vaccination substantially broadened the antigen display landscape, nearly doubling the proportion of tumor proteins presented in the immunopeptidome.",
      "evidence_line_refs": ["L28"]
    },
    {
      "id": "Q02",
      "metric": "Fraction of proteins represented in MHC-I peptidome",
      "value": "40.6%",
      "comparator_or_baseline": "20.6% (comparator)",
      "interpretation": "MHC-I antigen presentation capacity nearly doubled following vaccination, suggesting enhanced tumor visibility to cytotoxic T-cell surveillance.",
      "evidence_line_refs": ["L29"]
    },
    {
      "id": "Q03",
      "metric": "Retrospective human survival comparison p-value",
      "value": "p=0.01",
      "comparator_or_baseline": "N/A",
      "interpretation": "The vaccinated subgroup demonstrated statistically significant improved survival under ICI treatment compared to unvaccinated patients.",
      "evidence_line_refs": ["L30"]
    },
    {
      "id": "Q04",
      "metric": "Type I interferon response score (normalized units)",
      "value": "3.1",
      "comparator_or_baseline": "1.0 (comparator)",
      "interpretation": "Marked induction of type I interferon signaling was observed in tumors following mRNA vaccination, indicating robust innate immune activation.",
      "evidence_line_refs": ["L31"]
    },
    {
      "id": "Q05",
      "metric": "PD-L1 expression fold-change in tumor tissue",
      "value": "2.4x",
      "comparator_or_baseline": "1.0x (comparator)",
      "interpretation": "PD-L1 expression increased substantially in tumor tissue following treatment, rendering the checkpoint axis more targetable for ICI therapy.",
      "evidence_line_refs": ["L32"]
    },
    {
      "id": "Q06",
      "metric": "Intratumoral CD8+ T-cell density fold-change",
      "value": "1.8x",
      "comparator_or_baseline": "1.0x (comparator)",
      "interpretation": "Combination therapy resulted in nearly doubled CD8+ T-cell infiltration into tumors, indicating enhanced immune cell recruitment and tumor infiltration.",
      "evidence_line_refs": ["L33"]
    }
  ],
  "controls_or_null_results": [
    {
      "statement": "Vaccine-only treatment did not produce durable tumor control in non-immunogenic models, demonstrating the necessity of combining mRNA vaccination with checkpoint blockade.",
      "evidence_line_ref": "L36"
    },
    {
      "statement": "ICI-only treatment had limited activity in low-immunogenic baseline settings, highlighting the importance of prior immune priming through vaccination.",
      "evidence_line_ref": "L37"
    },
    {
      "statement": "Lipid particle controls lacking mRNA did not reproduce the sensitization effect, confirming that the mRNA component is essential for the observed biological activity.",
      "evidence_line_ref": "L38"
    },
    {
      "statement": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit, demonstrating that interferon signaling is mechanistically required for the vaccine's effects.",
      "evidence_line_ref": "L39"
    }
  ]
}